Latest PKY News

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Pathkey.AI has completed a strategic review, bolstered its leadership team, and secured $3.5 million in funding to accelerate growth and broaden its AI platform's applications beyond clinical trials.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

Pathkey.AI has secured A$2.5 million through a placement and launched a nearly A$1 million rights issue to fund expansion of its AI-driven TrialKey platform and pursue strategic acquisitions, alongside key board changes.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.